Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selective...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2022-12-01
|
| coleção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2141978 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|